Recently, the FDA drafted this guidance document to help the medical device industry make decisions around manufacturing site changes. This guidance is intended to help in managing the time frames for changes in manufacturing sites and the associate changes to processes, methods, procedures, qualifications and validations by helping industry predict when an FDA pre-approval inspection is likely to be required for a manufacturing site change.

Sections related to computers and software:

Section III Part A – Definitions

Part A includes software in the list of medical device components.

Section IV Part A – Site Change Supplement vs. 30-day Notice

Part A requires a 30-Day Notice for three categories of changes to the manufacturing of critical components:

  1. Change to out-sourcing
  2. Changing the outsourcing provider
  3. Change to in-sourcing

Section IV Part B – Site Change Supplement Contents

Part B recommends including the validation or revalidation plan for software used as part of the production or quality system.

Download the FDA draft guidance here: Manufacturing Site Change Supplements: Content and Submission

Not what to make of these recommendations? Talk to our CSV experts about how you might be affected.

Like it? Share it:

You may also like

Are Active Pharmaceutical Ingredient Manufacturers Compliant With New FDA GMP Guidance?
10 December, 2016

In September, the FDA published Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients to provide AP...

Are you ready for the FDA guidance on the design of Interoperable Medical Devices?
11 February, 2016

If your electronic medical device exchanges data with other devices, you need to read the new draft guidance just publis...

AI & CGMP: FDA's 1st Warning Letter on Non-Compliant AI in Manufacturing
23 April, 2026

The FDA’s April 2026 Warning Letter to Purolea Cosmetics Lab is a notable milestone for the pharmaceutical industry. Whi...